MoonLake Immunotherapeutics (MLTX)
11.07
+0.04
(+0.36%)
USD |
NASDAQ |
Nov 20, 16:00
11.07
0.00 (0.00%)
After-Hours: 20:00
MoonLake Immunotherapeutics Enterprise Value : 545.29M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 545.29M |
| November 19, 2026 | 541.88M |
| November 18, 2026 | 521.46M |
| November 17, 2026 | 560.60M |
| November 16, 2026 | 601.46M |
| November 13, 2026 | 666.99M |
| November 12, 2026 | 698.48M |
| November 11, 2026 | 752.95M |
| November 10, 2026 | 672.09M |
| November 09, 2026 | 677.20M |
| November 06, 2026 | 584.43M |
| November 05, 2026 | 522.31M |
| November 04, 2026 | 586.99M |
| November 03, 2026 | 598.90M |
| November 02, 2026 | 579.33M |
| October 30, 2026 | 605.71M |
| October 29, 2026 | 672.95M |
| October 28, 2026 | 650.82M |
| October 27, 2026 | 618.48M |
| October 26, 2026 | 608.26M |
| October 23, 2026 | 611.67M |
| October 22, 2026 | 653.37M |
| October 21, 2026 | 509.54M |
| October 20, 2026 | 481.46M |
| October 19, 2026 | 432.94M |
| Date | Value |
|---|---|
| October 16, 2026 | 415.92M |
| October 15, 2026 | 476.35M |
| October 14, 2026 | 466.14M |
| October 13, 2026 | 489.11M |
| October 12, 2026 | 512.09M |
| October 09, 2026 | 524.01M |
| October 08, 2026 | 503.58M |
| October 07, 2026 | 519.75M |
| October 06, 2026 | 535.07M |
| October 05, 2026 | 571.67M |
| October 02, 2026 | 574.22M |
| October 01, 2026 | 579.33M |
| September 30, 2026 | 598.90M |
| September 29, 2026 | 521.80M |
| September 28, 2026 | 531.00M |
| September 25, 2026 | 571.13M |
| September 24, 2026 | 577.82M |
| September 23, 2026 | 643.03M |
| September 22, 2026 | 683.16M |
| September 21, 2026 | 613.77M |
| September 18, 2026 | 600.39M |
| September 17, 2026 | 597.04M |
| September 16, 2026 | 606.24M |
| September 15, 2026 | 584.50M |
| September 14, 2026 | 624.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 37.36B |
| AC Immune SA | 93.79M |
| CRISPR Therapeutics AG | 2.294B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -79.54M |
| Total Expenses (Quarterly) | 79.54M |
| EPS Diluted (Quarterly) | -0.9316 |
| Earnings Yield | -33.13% |
| Normalized Earnings Yield | -33.13 |